9 Feb 2015

VBL Therapeutics to Present Preclinical Data at Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease

Customize font size:

TEL AVIV, Israel, Feb. 9, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory disease, today announced that Eyal Breitbart, Ph.D., Vice President of Research and Operations of VBL, will present preclinical results evaluating the Company's lead Lecinoxoid candidate, VB-201, for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis, in an oral presentation at the Keystone Symposium on Liver Metabolism and Nonalcoholic Fatty Liver Disease (NAFLD), taking place on March 22 - 27, 2015 in Whistler, British Columbia, Canada. The reported data will include preclinical results in mice with NASH and liver fibrosis, and will assess key measures of efficacy related to inflammation and fibrosis.

With a novel mechanism of action designed to mimic naturally occurring oxidized phospholipids with anti-inflammatory properties, VB-201 has the potential to address a range of chronic, immune-inflammatory and inflammatory-derived diseases. VBL recently completed two Phase 2 studies evaluating the efficacy of lead Lecinoxoid compound, VB-201, for the treatment of psoriasis and ulcerative colitis. Top line results from both studies are expected in the first quarter of 2015.

Fibrosis is a major pathological feature of many chronic autoimmune diseases and Toll-like receptors (TLRs) have been implicated as being a part of the underlying pathogenesis. Driven by the mechanism of action of VB-201, which inhibits the TLR2 and CD14/TLR4 complexes as well as monocyte migration, VBL explored VB-201 in a liver fibrosis model as proof of concept for additional target indications.

Details of the presentation are as follows:

Title: Oxidized-Phospholipid Small Molecule Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis.

Session Title: Workshop 2: NAFLD Therapeutics

Session Date: Wednesday, March 25, 2015

Session Time: 2:30 PM – 4:30 PM

Presenter: Eyal Breitbart, Ph.D., Vice President of Research and Operations, VBL Therapeutics